The vaccine will be based on recombinant avian paramyxovirus-based vector platform, IITG said in a statement.
“IITG and Hester Biosciences expect the vaccine to be ready by the end of this year to start animal studies. The work is currently in its early stage of development,” it added
The premier educational institute said that the recombinant avian paramyxovirus-1 will be used to express the immunogenic protein of SARS-CoV-2. “The team at IITG has generated the recombinant avian paramyxovirus-1 based vaccine platform for Classical Swine Fever and Japanese Encephalitis. The role of the institute is to produce the recombinant vaccine candidate,” it added.
“The recombinant avian paramyxovirus-1 expressing the SARS-CoV-2 protein could be used as a vaccine candidate for further study,” it added.
Head of the research team Sachin Kumar, who is Associate Professor in the Department of Biosciences and Bioengineering at IIT Guwahati, said “It is too early to comment on the efficacy and immunogenicity of the vaccine, however, we will be able to reveal more details about this vaccine after the results of animal studies are obtained”.
“IITG and Hester have collaborated to develop and manufacture a recombinant vaccine against COVID-19 disease as a preventive measure. Hester’s involvement would be from master seed development up to release of the commercial vaccine,” Rajiv Gandhi, CEO and MD, Hester Biosciences said.
The agreement between the two organisations was signed earlier this month.
- Angola, DRC combat yellow fever outbreak — UN health agency
- Meet the women under 40 unlocking new ways to treat diseases and shaping the future of medicine
- These 20 VC-backed companies had the biggest exits of the last year
- No reason to panic – Sanofi
- California is struggling with the largest and deadliest hepatitis A outbreak to hit the US in decades
- A year ago, Google blew itself up to become Alphabet — and a lot has changed since then …
- In Asia Pacific, one death every 30 seconds from viral hepatitis
- Risky sexual behavior precipitates HIV, cancer
- UN appeals for more funds for typhoon victims
- ‘The outlier thing didn’t work out’ — Biotech CEOs reflect on Theranos’ impact on the industry
- A Wall Street firm is giving service-disabled vets an opportunity
- PrEP: A shield against AIDS
- HIV, teen pregnancy stalk Filipino youth – senator
IIT-Guwahati partners with Hester Biosciences for COVID-19 vaccine have 454 words, post on www.gadgetsnow.com at April 29, 2020. This is cached page on Talk Vietnam. If you want remove this page, please contact us.